Skip to main content

Transgenomic Will Move to Nasdaq's Cap Market, Has Until Feb. 12 to Regain Compliance

NEW YORK (GenomeWeb News) – Transgenomic yesterday said that the Nasdaq Exchange has given the company an additional 180 calendar days, or until Feb. 12, 2007, to regain compliance with its minimum $1 bid requirement.
As GenomeWeb News reported Aug. 2, Transgenomic asked the Nasdaq Exchange to transfer its stock from the Global Market to the Capital Market in a bid to win time and regain compliance. Moving to the new market would give the company an additional 180 days to lift its shares above the $1 bid minimum.
The Nasdaq approved the move Aug. 7 and Transgenomic's common stock began trading on the Nasdaq Capital Market Aug. 10. 
Like the Global Market, the Capital Market has a $1 minimum bid requirement, and for the company to regain compliance its common stock must close at or above $1 per share for at least 10 consecutive business days.
The Nasdaq's Listing Qualifications Department on Feb. 15 had originally informed Transgenomic that it was in violation of its listing standards and gave the company 180 days, or until Aug. 14, to regain compliance.
Transgenomic’s stock closed at $.47 on Aug. 14. The last time the company’s stock closed at or above $1 was Feb. 14.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.